Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gap junction alpha-4 protein (GJA4 or Connexin-37) is a member of the connexin family that forms gap junction channels connecting the cytoplasm of adjacent cells, especially in vascular endothelial tissues. These channels provide a direct pathway for the diffusion of ions and small molecules (up to 1 kDa), supporting essential physiological processes such as electrical coupling, metabolic cooperation, and coordinated cellular responses. Mutations or dysregulation of GJA4 are associated with vascular pathologies, including increased risk of atherosclerosis and hemangiomas[1][4].
Formation of gap junction channels allowing intercellular transfer of ions and small molecules; inhibition may modulate vascular function and thrombosis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gap junction alpha-4 protein (GJA4).